Palobiofarma starts clinical trials on the first adenosine-based drug developed in Spain for the treatment of Parkinsonʼs disease

Lyhen Gonzalez (researcher), Nahomi Castro (project manager), Julio Castro (director general) and Juan Camacho (scientific director).
Lyhen Gonzalez (researcher), Nahomi Castro (project manager), Julio Castro (director general) and Juan Camacho (scientific director).
Research
(26/11/2012)

Palobiofama, SL, a biotechnology company located at the Barcelona Science Park, has started clinical trials of its first drug, the compound PBF-509, a potent antagonist of the adenosine A2a receptors. The drug, discovered, developed, and patented entirely by Palobiofarma, is a very innovative treatment that aims to improve movement and cognitive disorders in patients who suffer Parkinson's disease. In order to treat this disease there are only drugs with a palliative effect.

Lyhen Gonzalez (researcher), Nahomi Castro (project manager), Julio Castro (director general) and Juan Camacho (scientific director).
Lyhen Gonzalez (researcher), Nahomi Castro (project manager), Julio Castro (director general) and Juan Camacho (scientific director).
Research
26/11/2012

Palobiofama, SL, a biotechnology company located at the Barcelona Science Park, has started clinical trials of its first drug, the compound PBF-509, a potent antagonist of the adenosine A2a receptors. The drug, discovered, developed, and patented entirely by Palobiofarma, is a very innovative treatment that aims to improve movement and cognitive disorders in patients who suffer Parkinson's disease. In order to treat this disease there are only drugs with a palliative effect.

More information on this link